Note: Descriptions are shown in the official language in which they were submitted.
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
1
ENCAPSULATION METHOD
FIELD OF INVENTION
The present invention is within the field of encap-
sulating active substances, e.g. drugs, in biodegradable
polymers. More specifically the invention relates to a
novel advantageous encapsulation method which is suitable
for water soluble as well as water insoluble active sub-
stances and which gives highly active micro as well as
nanoparticles with high encapsulation efficiency.
BACKGROUND OF THE INVENTION
The encapsulation of materials may provide benefi-
cial properties. For example, drugs that are encapsulated
may provide increased stability, longer duration of ac-
tion and increased efficiency. For convenience drugs are
often encapsulated in solid materials which have a size
suitable for injection, that is generally below 200 m in
diameter, and then the process is referred to as a micro-
encapsulation.
Microencapsulation processes may yield microcap-
sules, microspheres or microparticles. Microcapsules con-
sist of a core and a shell that covers the core. The
core may be composed of another polymer than the shell or
of another material altogether, e.g. of the active sub-
stance itself. The active substance is generally located
in the core but may also be located in the outer shell.
Microspheres are spherical in shape and have a more ho-
mogenous matrix. Microparticle is a more general term
than microspheres in that it is not restricted to spheri-
cal shapes. Sometimes it can be difficult to distinguish
between microcapsules, microspheres and microparticles,
and the term microparticles will be used herein with ref-
erence to all three classes.
Methods of preparing microparticles in the prior art
have been described extensively in both the patent and
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
2
the scientific literature (see e.g. Jalil R, Nixon JR.
Biodegradable poly(lactic acid) and poly(lactide-co-
glycolide) microcapsules: problems associated with prepa-
rative techniques and release properties. J Microencapsul
1990;7:297-325). They may generally be classified in
three types, which are exemplified below in connection
with the preparation of microspheres of poly(lactide-co-
glycolide) (PLGA). PLGA is a well accepted polymer for
preparing sustained release microspheres and often the
first choice for preparing biocompatible microspheres in-
tended for parenteral administration in humans. Said
polymer is not soluble in water.
1. Phase separation techniques using coacervating
agents, or non solvents, such as mineral oils and vegeta-
ble oils. The active substance, e.g. a polypeptide is
first dissolved in the aqueous phase of a water-in-oil
emulsion. The polypeptide can also be dispersed directly
in the polymer phase as a fine powder. Polymer is pre-
cipitated either around the aqueous droplets, or on the
polypeptide powder, by the addition of a non-solvent for
the polymer, such as silicon oil. Then a hardening agent
is added to extract the organic solvent from the micro-
spheres. The main disadvantage with said process is the
large amount of organic solvent needed for extraction and
for washing. The previously used hardening agents includ-
ing freons, hexane, heptane, cyclohexane and other alkane
solvents leave substantial amounts of hardening agents
residues in the microspheres and/or necessitate extensive
procedures for removing the solvent. Often very large
amounts of the second organic solvent are needed and they
are often undesirable for health, economical and environ-
mental reasons. Examples in the prior art include heptan
(EP 0 052 510), aliphatic fluorinated and fluorohalogen-
ated hydrocarbons sold as FREONS (SE 462 780), and other
(US 5,000,886). A further drawback when using e.g. an al-
kane hardening solvent is that it is flammable. Another
drawback is the impact thereof on the environment.
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
3
2. Spray drying and spray coating
In spray drying the polymer and the drug are mixed
together in a solvent for the polymer. The solvent is
then evaporated by spraying the solution. This results in
polymeric droplets containing the drug. However, sensi-
tive substances such as proteins can be inactivated dur-
ing the process due to the elevated temperatures used and
the exposure to organic solvent/air interfaces. Further
disadvantages include generation of high porosity due to
rapid removal of the organic solvent. A variation that
has been introduced to avoid these shortcomings is the
use of low temperature during microsphere formation (US
5,019,400, WO 90/13780 and US 4,166,800). Microcapsules
have been prepared using spray coating of drug-containng
microparticles with PLGA polymers (US 4,568,559).
3. Solvent evaporation
In solvent evaporation techniques the polymer is
dissolved in an organic solvent which contain the dis-
persed active drug, the solution then being added to an
agitated aqueous outer phase which is immiscible with
the polymer. The aqueous outer phase usually contains
surfactants to stabilise the oil-in-water emulsion and to
prevent agglomeration. The emulsifier used is typically
polyvinylalcohol. Emulsifiers are included in the aqueous
phase to stabilise the oil-in-water emulsion. The organic
solvent is then evaporated over a period of several hours
or more, thereby solidifying the polymer to form a poly-
meric matrix . The solvent can also be extracted by add-
ing the above mentioned suspension to a large volume of
water (US 5,407,609).
The final formulation to be used for pharmaceutical
applications, especially for parenteral administration,
should consist of discrete, non-agglomerated microspheres
with the desired size distribution and containing no
toxic or in any other way undesirable substances. In or-
der to obtain preparations having the characteristics de-
scribed above it is necessary to use emulsifiers. The
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
4
emulsifier can serve several purposes: (1) assist in ob-
taining the correct droplet size distribution of the
emulsion; (2) stabilise the oil-in-water emulsion to
avoid coalescence of the droplets; and (3) prevent the
solidified microspheres from sticking to each other. The
most commonly used emulsifier for preparing PLGA micro-
spheres is polyvinyl alcohol. However, since polyvinyl
alcohol is listed in the 1976 Register of Toxic Effects
of Chemical Substances and is also implicated as carcino-
genic when introduced parenterally into animals
("Carcinogenic studies on Water-Soluble and Insoluble
Macromolecules", Archives of Pathology, 67, 589-617,
1959) it is considered undesirable for pharmaceutical
preparations administered by injection. This problem has
been recognized and attempts of replacing polyvinyl alco-
hol with other emulsifers can be found in the prior art,
for example in US 4,384,975, wherein a carboxylic acid
salt surfactant, e.g. sodium oleate was used to stabilise
an oil-in-water emulsion. However, despite its drawbacks
polyvinyl alcohol is still the most videly used surfac-
tant. However, for the above-mentioned reasons it would
be highly desirable to avoid the use of polyvinyl alcohol
and other surfactants in microsphere preparations.
Solvent evaporation works well for hydrophobic drugs
but for hydrophilic drugs, such as many peptides and pro-
teins, the amount of incorporated drug can be low due to
loss of drug to the aqueous phase which is used to ex-
tract the organic solvent. Attempts to circumvent this
problem include modifying the hydrophilic drug into a
less soluble form (WO 96/07399) increasing the viscosity
of the inner aqueous solution containing the active drug
in a process where a water-in-oil emulsion is first cre-
ated and the organic solvent then extracted with water
(US 4,652,441) and reducing the time available for diffu-
sion (US 5,407,609).
Further, the use of the commonly employed organic
solvents, like methylene chloride or ethyl acetate, often
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
results in loss of biological activity for sensitive
drugs. Thus, for instance for proteins the three dimen-
sional conformation which is required for biological ac-
tivity is often lost. Attempts to circumvent this problem
5 includes modification of the active substance into a more
stable form (US 5,654,010 and WO 96/40074) keeping the
temperature as low as possible during the process (WO
90/13780), and using different protein stabilisers (US
5,589,167, Cleland JL, Jones AJS, "Development of stable
protein formulations for microencapsulation in biodegra-
dable polymers". Proceedings of the International Sympo-
sium on Controlled Release of Bioactive Materials
1995;22:514-5). However, proteins are generally sensitive
to organic solvents and reducing or eliminating the expo-
sure is highly desirable.
Another disadvantage with the solvent evaporation
method is the need for using high shear mixing in order
to obtain small microspheres or nanospheres. This may re-
sult in degradation or conformational changes of the ac-
tive substance, especially if it is a protein which is
dependent on a three dimensional conformation for its
biological activity. The use of high shear mixing is also
energy consuming.
In connection with the prior art it can also be
added that processes for preparing microspheres from
polymers soluble in water are known from e.g. US
4,822,535 and US 5,578,709. In said processes two mutu-
ally immiscible aqueous liquid phases are used, of which
one is solidified into microspheres. However, as said,
these methods cannot be used for the preparation of mi-
crospheres from polymers that cannot be dissolved in wa-
ter.
The present invention relates to a novel method of
encapsulating active substances in biodegradable polymers
by which the prior art disadvantages are eliminated or at
least essentially reduced. For instance the invention
makes it possible to obtain high incorporation efficiency
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
6
of the active substance-in the biodegradable polymer
and/or to accomplish smaller microparticles or even nano-
particles containing'highly active doses of the active
substances. Furthermore, the amounts of organic solvents
are highly reduced. As compared to previously used meth-
ods the invention also enables a reduction of the energy
input required to obtain micro- or nanoparticles.
OBJECTS OF THE INVENTION
One object of the invention is to provide a method
of preparing controlled or sustained release particles
having a high entrapment of water soluble substances,
e.g. sensitive drugs, without the use of large volumes of
organic solvents.
Another object is to provide a method wherein low
energy mixing is utilized only, which is also advanta-
geous in connection with sensitive substances.
Still another object is to provide a method by.which
small particle sizes, such as micro or even nano size
particles, can be obtained in a simple way.
One other object is to provide a method by which the
requirement for using PVA and other surfactants is elimi-
nated.
Other objects of the invention should be clear to a
person skilled in the art when reading the description
above and below.
SUMMARY OF THE INVENTION
More specifically the present invention relates to a
method of encapsulating an active substance in a biode-
gradable polymer, which method comprises:
a) dissolving said biodegradable polymer in an organic
solvent therefor;
bl) dispersing said active substance in the organic so-
lution obtained in step a), to provide a dispersion with
the active substance as the inner phase thereof; or al-
ternatively
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
7
b2) emulsifying said active substance, dissolved in wa-
ter or other aqueous sdlvent therefor, in the organic so-
lution obtained in step a), to provide an emulsion with
the active substance as the inner aqueous phase thereof;
and
c) subjecting the dispersion obtained in step bl), or
alternatively the emulsion obtained in step b2), to an
encapsulation operation with an aqueous polyethylene
glycol solution as a continuous phase, so as to obtain
micro- or nanoparticles having the active substance en-
capsulated therein.
Thus, according to one aspect of the invention there
is provided a simple method of preparing micro- or nano-
particles containing a sensitive biologically active ma-
terial, e.g. a protein, while using minimal amounts o-f
organic solvent. It has surprisingly been found possible
to replace the normally used organic solvent as the con-
tinous or extraction phase by an aqueous solution of the
non-toxic and pharmaceutically acceptable polymer poly-
ethylene glycol (polyethylene oxide) as a continuous
phase and as an extraction medium.
It has also been found that the uptake of active in-
gredient into the particles can be markedly improved by
said use of polyethylene glycol in water or other aqueous
solvent as outer(external) phase. The use of solvent
evaporation techniques with an aqueous outer phase often
results in poor encapsulation as water soluble polypep-
tides are distributed also to the external phase, espe-
cially when small microspheres are obtained. With the
present invention high loading combined with small parti-
cle size can be obtained provided that the concentration
of polyethylene glycol, and other conditions, are con-
trolled such that the active substance is not distributed
to the outer phase.
The microparticles can easily be washed and rinsed
with water, which is an advantage as compared to the
phase separation technique where large amounts of organic
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
8
solvents are used. Other.surprising findings in connec-
tion with the use of polyethylene glycol/aqueous solvent
as outer phase is that small sized particles are obtained
even with low mixing forces and that no surfactants are
needed.
The obtained microparticles are well suited for sus-
tained release purposes and are especially adapted for
oral or parenteral administration. When prepared with
sizes or diameters of less than 10 pm, and preferably
0.5-3 pm, they are also suitable for nasal or pulmonal
administration to provide either local or systemic ef-
fect.
In addition to the unexpected findings referred to
above it should also be noted that polyethylene glycol
(PEG) is previously known per se to have unique proper-
ties for a variety of biotechnical and biomedical appli-
cations, which makes the present invention even more ad-
vantageous for biotechnical and biomedical applications.
These unique properties are e.g. summarized in Har-
ris, J.M. (ed) Poly(ethylene glycol) chemistry: biotech-
nical and biomedical applications. 1992, Plenum Press,
New York.
PEG has unique properties of major importance for
its use in a variety of biotechnical and biomedical app-
lications. One of these is its outstanding effectiveness
in excluding other polymers from the volume it occupies
in a water solution, which has been utilised to obtain
rejection of proteins e.g. in liposomes and small parti-
cles with long circulation times after intravenous injec-
tion, hospitability to biological materials, non-
immunogenicity and non-antigenicity. Another is the for-
mation of aqueous two-phase systems with other polymers
(Per Ake Albertsson, Partition of cell particles and mac-
romolecules. Separation and purification of biomolecules,
cell organelles, membranes, and cells in aqueous polymer
two-phase systems and their use in biochemical analysis
and biotechnology. Third Edition, 1986, John Siley &
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
9
Sons). PEG is non-toxic and.generally harmless to pro-
teins and cells. Of the=numerous applications of PEG can
be mentioned: (1) as a co-solvent for some drugs for in-
jection, (2) as a volume-excluder to increase the concen-
tration of e.g. proteins to induce crystallization, (3)
as a part of aqueous two-phase systems used for e.g. pu-
rification of biological materials under mild conditions,
(4) induction of cell fusion to obtain e.g. hybridomas
used for production of monoclonal antibodies, (5) cover-
ing the surface of e.g. liposomes and nanoparticles to
increase their residence time in the circulation, and (6)
covalent attachment of PEG to proteins to obtain conju-
gates which are still biologically active but no longer
immunogenic and antigenic; such PEG-protein adducts hav-
ing been approved for parenteral use in humans.
PEGs are also sometimes referred to as poly(ethylene
oxide) PEO, poly(oxyethylene) and polyoxirane. In general
usage, poly(ethylene glycol) refers to molecular weights
below 20000, and poly(ethylene)oxide refers to higher mo-
lecular weights polymers. In other words the term poly-
ethylene glycol as used in connection with the invention
covers also poly(oxyethylene) and polyoxirane.
These objects as well as other objects and advan-
tages of the present invention will become apparent to
those skilled in the art from the description following
below.
DETAILED DESCRIPTION OF THE INVENTION
The active substances to be used in the method of
the invention are preferable biologically active
subtances, e.g. drugs, such as proteins, peptides,
polypeptides, polynucleotides, oligonucloetides, plas-
mides or DNA. Examples of protein drugs are growth hor-
mone, erythropoietin, interferon(a,P,y-type), vaccines,
epidermal growth hormone and Factor VIII. Examples of
peptide drugs are LHRH analogues, insulin, somatostatin,
calcitonin, vasopressin and its derivatives.
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
In the case of proteins they can also be complexed
with various substances, e.g. metals, amino acids, salts,
acids, bases and amines, to decrease solubility or in-
crease stability. They can further be prepared in the
5 form of a pro-drug or PEG can be attached e.g. to the
proteins to increase solubility or stability, modify
pharmacokinetics or reduce immunogenicity.
Examples of non-protein drugs suitable for use in
the method of the invention can be found for example in
10 the following groups:
anti-tumor agents, antibiotics, anti-flammatory agents,
antihistamines, sedatives, muscle relaxants, antiepilep-
tic agents, antidepressants, antiallergic agents, bron-
chodilators, cardiotonics, antiarrythmic agents, vasodi-
lators, antidiabetic agents, anticoagulants, hemostatics,
narcotic agents and steroids.
The active substances which can be encapsulated in
accordance with the method claimed are, however, not re-
stricted to biologically active substances, non-
biological substances can be encapsulated, e.g. pesti-
cides, fragrances, flavouring agents, catalysts and her-
bicides.
The proper amount of active substance to be encapsu-
lated is dependent on type of substance, duration time
and desired effect, and is of course controlled to an
amount that is in each specific case encapsulable by the
method according to the invention. Generally said amount
is chosen within the range of about 0,001% to 90%, pref-
erably about 0,01 to 70%, more preferably about 0.1 to
45%, and most preferably about 0.1 to 40%, said percent-
ages being by weight based on the weight of the final
particles.
In the case of a drug the substance can be used per
se or in the form of a pharmaceutical salt. When the drug
has a basic group, such as amino groups, it can form
salts with carbonic acid, hydrochloric acid, sulphuric
acid, acetic acid, citric acid, methanesulfonic acid or
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
11
the like. When the drug has an acidic group, such as a
carboxyl group, it can form salts with metals(e.g. Ca;+'
Zn2+), organic amines-(e.g. ethanolamine) or basic amino
acids (e.g. arginine). The drug can further be precipi-
tated using various means, optionally followed by size
reduction, such as precipitation with divalent metals
(e.g Ca2+' Zn2+) . The drug may also be crystallized.
The biodegradable polymer that can be used in the
present invention is not limited to any specific material
as long as it can be dissolved in an organic solvent and
is slightly soluble or insoluble in the outer phase, e.g.
poly(ethylene glycol)/aqueous phase and is otherwise
suitable for the preparation of sustained release micro-
or nanoparticles.
Preferably the biodegradable polymer used in the;,
method claimed has a weight average molecular weight in
the range of about 2000 to 200000, more preferably about
2000 to 110000.
Examples of biodegradable polymers are polyesters,
poly-(3-hydroxybutyric acid, polyhydroxyvaleric acid,
polycaprolactone, polyesteramides, polycyanoacrylates,
poly(amino acids), polycarbonates and polyanhydrides.
A preferred biodegradable polymer is an aliphatic
polyester, e.g. homo or copolymers prepared from a-
hydroxy acids, preferably lactic acid and glycolic acid,
and/or cyclic dimers of a-hydroxy acids, preferably lac-
tides and glycolides.
When lactic acid/glycolic acid are used as the
above-mentioned polymers, the composition or weight ratio
(poly)lactic acid/(poly)glycolic acid is preferably about
99/1 to 35/65, more preferably 95/5 to 50/50. They may be
used in the form of a copolymer or a mixture of these two
or more polymers. The exact composition of the polymer
depends on the desired relase kinetics, especially the
duration of release.
The organic solvent used in step A can be any sol-
vent that is capable of forming an emulsion with a wa-
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
12
ter/PEG mixture, can be removed from the oil droplets
through said water/PEG mixture and is capable of dissolv-
ing the biodegradablo polymer. In other words the solvent
should be immiscible, or essentially immiscible, but
slightly, or very slightly, soluble in said water/PEG
mixture. Examples of suitable solvents are ethyl acetate,
dichloromethane, methyl ethyl ketone and methyl isobutyl
ketone. These solvents can be used alone or in combina-
tions.
The inner aqueous phase may contain agents for con-
trolling the stability and, if desired, the solubility of
the biologically active substance. Such agents may be pH
controlling agents and stabilizers for drugs or other ac-
tive substances.
As can be gathered from the above-mentioned the
method according to the invention can be utilized to en-
capsulate water soluble as well as water insoluble active
substances.
Examples of embodiments of these two cases will now
be presented below.
The encapsulation method, as exemplified by a water
soluble drug, such as a peptide or protein drug can com-
prise the following steps. The drug solution is prepared
in any conventional way and optionally while using pH
controlling or drug stabilizing agents. This aqueous so-
lution of the drug, which is to form the inner aqueous
phase, is poured into an external (oil) phase containing
a biodegradable polymer dissolved in a suitable organic
solvent and the mixture is emulsified to provide a W/O
emulsion. The emulsification can be prepared using con-
ventional emulsification techniques, such as, propeller
mixing, turbine mixing, ultrasonication or use of static
mixers.
If the active substance is to be dispersed directly
in the polymer solution, without being dissolved in wa-
ter, the drug should have a suitable particle size. A
suitable particle size is about 0.5-20 pm, preferably
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
13
0.5-10 pm, such as 0.5-3 pm. Otherwise, the dispersion
step can be carried out as described above for the emul-
sification step.
The resulting W/O emulsion/dispersion is then sub-
jected to an encapsulation operation. The W/O emul-
sion/dispersion is added to an aqueous solution contain-
ing polyethylene glycol. The polyetylene glycol/aqueous
solution is stirred during the addition of the active
substance/polymer solution. The W/O emulsion/dispersion
can also be mixed with the polyethylene glycol solution
by using motionless mixers.
Typically the molecular weight of the polyethylene
glycol is within the range of about 1000 to 40000 Da,
preferably 5000 to 35000 Da. Depending on said molecular
weight, and the properties of the substance to be encap-
sulated, the concentration of polyetylene glycol is con-
trolled within the range of 20-80% (w/w), preferably 20-
60% (w/w), such as 30-55% (w/w) or 30-50% (w/w). In other
words a relatively high PEG concentration is used in the
outer phase, to obtain a stable emulsion and to prevent
diffusion of active ingredient from the droplets/par-
ticles. The determination of the optimal concentration
can be made by experimentation that is relatively
straightforward to someone skilled in the art.
The particles thus formed are generally collected by
centrifugation or filtration and rinsed with distilled
water or suitable aqueous buffers, several times to re-
move the excess of polyethylene glycol from the surfaces.
To prevent aggregation during the washing and drying pro-
cedure, mannitol, Tween 80, or other suitable substan-
ces, may be added to the rinsing water. The particles
thus obtained can then be dried by conventional means,
for instance in vacuum or by a streaming nitrogen gas
flow or by lyophilization or air suspension drying.
The particle sizes of the particles obtained by the
invention are dependent on the desired uses of said par-.
ticles as is well known within this technical field.
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
14
Thus, for instance, when the particles are intended for
injection, the particle size should satisfy the dispersi-
bility and needle passage requirements. Furthermore, the
particles can be handled or treated in any manner previ-
ously known to a person skilled in the art. Thus, a
controlled release injectable preparation of said parti-
cles can e.g. be dispersed with a suspending agent, con-
taining e.g. mannitol, polysorbate 80, or sodium carboxy-
methylcellulose.
Other embodiments of the method according to the in-
vention are defined in sub-claims or in the Examples pre-
sented below.
According to a second aspect of the invention there
are also provided sustained release micro or nanoparti-
cles per se containing an active substance encapsulated
in a biodegradable material, which particles are obtain-
able by a method as claimed in any one of the method
claims.
Thus, preferable embodiments thereof are the same as
those embodiments which are described in connection with
the method. Especially preferable are, however, particles
which are adapted for oral, parenteral, nasal or pulmonal
administration of the active substance.
Furthermore, for the manufacture of pharmaceutical
preparations for oral administration, the microspheres
prepared by the method described may be formulated with
an excipient (e.g. lactose, sucrose, starch etc.), a dis-
integrant (e.g. starch, calcium carbonate, etc.), a
binder (e.g. starch, gum arabic, carboxymethylcellulose,
polyvinylpyrrolidone, etc.) and/or a lubricant(e.g. talc,
magnesium stearate, polyethylene glycol etc.) and the re-
sulting composition can be compression-molded in conven-
tional manner. The particles can also be filled into
gelatine capsules.
FIGURE
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
In the accompanying drawing figure the results of in
vitro release tests are presented for particles obtained
by the method of the-present invention as well as parti-
cles obtained in line with the prior art.
5 The manufactures of said particles and the test
method are described in Examples 1-5 and the results are
presented as cumulative release in % versus time in days.
In this context it can also be added that the re-
lease profile can be controlled by factors well known to
10 anyone skilled in the art, e.g. the composition of the
polymer used for encapsulating the active material, the
solubility of the material, addition of substances af-
fecting the solubility of the active material and/or de-
gradation of the polymer, the amount of active material
15 in the microparticles and the size of the microparticles.
EXAMPLE 1
The following procedure was used to encapsulate bo-
vine serum albumin (BSA) in PLGA (poly(DL-lactide-co-
glycolide)). First a polymer solution was prepared by
dissolving 0.47 g of PLGA (RG504H, Boehringer Ingelheim)
in 3 ml of ethyl acetate in a test tube. Then, 44 mg of
BSA, (bovine serum albumin; Sigma A-0281) was dissolved
in 300 ul of 10 mM Na-phosphate buffer pH 6.4. The BSA
solution was added to the polymer solution and the BSA
was homogenously dispersed in the polymer solution by
vortex mixing (VF2, IKA-WERK) for one minute. The disper-
sion was placed in a 5 ml syringe with an 18 G needle.
A 500 ml beaker containing 300 ml of 40%(w/w) polye-
tylene glycol 20000 was fitted with a 4-bladed propeller
stirrer. The BSA/polymer dispersion was transferred to
the beaker by slowly injecting the BSA/polymer dispersion
into the PEG solution. The stirrer speed was then reduced
and the mixture was left standing overnight.
The stirrer speed was set at 8 again and then 400 ml
of deionized water were added to reduce the viscosity in.
order to enable filtration. The suspension was then fil-
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
16
tered using a Millipore membrane filter, Type DV, pore
size 0.65 pm, washed with water (3x 300 ml) and dried in
vacuum overnight. -
The resulting microparticles were spherical with a
particle diameter of 10-50 pm and contained 6.3 % of BSA
(w/w) =
The resulting microparticles were then subjected to
an in vitro release test in 30 mM sodium phosphate pH 7.4
at 37 C, with intermittent agitation. The studies were
conducted by suspending 40 mg of microspheres in 1.5 ml
of buffer. At specified time points, 1 ml of the buffer
was withdrawn and replaced with fresh buffer. The results
are shown in figure 1. Sustained release of BSA was
achieved for 28 days as is shown in figure 1.
EXAMPLE 2
The same procedure was performed as in example 1 ex-
cept that 2% (w/w) polyvinyl alcohol (PVA, mw=22000,
Fluka)in water was used instead of the polyethylene gly-
col solution.
The resulting microspheres had a particle diameter
of 1-2 mm and contained 7.0% of BSA. An in vitro release
test was conducted as in example 1 and the results are
shown in figure 1. Sustained release for about 2 days was
achieved with this formulation. The large size would not
have permitted injection using acceptable needles.
EXAMPLE 3
The same procedure was performed as in example 1 ex-
cept that the an Ystral homogenizer was used instead of
said stirrer when adding the BSA/polymer dispersion. Af-
ter addition of the BSA/polymer dispersion the homoge-
nizer was replaced by the 4-bladed propeller stirrer.
The resulting microspheres had a particle diameter
of 1-5 pm and contained 5.5% of BSA. An in vitro release
test was conducted as in example 1 and the results are
shown in figure 1.
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
17
EXAMPLE 4
The same procedure was performed as in example 2 ex-
cept that the an Ystral homogenizer was used instead of a
stirrer when adding the BSA/polymer dispersion.
The resulting microspheres had a mean particle di-
ameter of 10-40 pm and contained 5.8% of BSA. An in vitro
release test was conducted as in example 1 and the re-
sults are shown in figure 1. Similar dissolution profiles
were obtained for the preparations in examples 3 and 4
even though the size of the particle in example 3 was
much smaller.
EXAMPLE 5
The same procedure was performed as in example 1 ex-
cept that an ultrasonic bath (Transsonic 470/H, Elma) was
used after the vortex mixing in order to obtain a finer
water-in-oil emulsion. The BSA/polymer dispersion was
sonicated for 1 minute.
The resulting microspheres had a mean particle di-
ameter of 10-50 pm and contained 6.8% of BSA. An in vitro
test was conducted as in example 1 and the results are
shown in figure 1. Sustained release for 28 days was
achieved. This shows that a more efficient emulsification
of the inner aqeuous phase results in a lower rapid ini-
tial release (burst) during the first days.
EXAMPLE 6
Preparation of BSA loaded microspheres
The following procedure was used to encapsulate Bo-
vine Serum Albumin (BSA) in PLGA microspheres.
First a polymer solution was prepared by dissolving
0.126 g of polymer (Resomer 504H, Boehringer Ingelheim)
with 0.734 of ethyl acetate in a test tube. Then 15 mg of
BSA (Sigma A-0281) were dissolved in 100 ul of 10 mM so-
dium phosphate pH 6.4.
The BSA solution was mixed with the polymer solution
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
18
by vortex mixing (VF2, IKA-WERK) for one minute. The so-
lution was withdrawn into a 2 ml syringe with a 21G nee-
dle. A 200 ml beaker-containing 50 ml of 40% (w/w) poly-
ethylene glycol 20000 was fitted with a 4-bladed propel-
ler stirrer. The BSA/polymer dispersion was slowly in-
jected into the PEG solution during stirring at 240 rpm.
The stirring speed was increased to 400 rpm for 10 sec-
onds then the stirring speed was 60 rpm for one minute.
The mixture was left standing unstirred for 4 hours.
200 ml of water were then added before filtration.
The microsphere suspension was filtered using a Millipore
membrane filter, Type DV, pore size 0.65 pm, washed with
water and then freeze-dried overnight.
The resulting microparticles were spherical with a
particle diameter of 10-50 pm and contained 9.7% of BSA
(92% yield).
EXAMPLE 7
Preparation of Lactoglobulin loaded microspheres
The same procedure was performed as in example 6,
except that 15 mg of Lactoglobulin (Sigma L-0130) in 100
pl 10 mM sodium phosphate pH 6.4 were used for encapsula-
tion.
The resulting microparticles were spherical with a
particle diameter of 10-100 pm and contained 9.9% of lac-
toglobulin (93% yield).
EXAMPLE 8
Preparation of Triptorelin loaded microspheres
The same procedure was performed as in example 6,
except that 15 mg of Triptorelin pamoate (Bachem) were
emulsified directly in the polymer solution by vortex
mixing for one minute. The particle size of triptorelin
particles was about 2-4 pm.
The resulting microparticles were spherical with a
particle diameter of 20-100 pm and contained 6.3% of
Triptorelin (59% yield).
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
19
EXAMPLE 9
Preparation of Desmopressin loaded microspheres
The same procedure was performed as in example 6,
except that 15 mg Desmopressin acetate in 100 l of 10 mM
sodium phosphate pH 6.4 were used for encapsulation.
The resulting microparticles were spherical with a
particle diameter of 10-50 m and contained 8.3% of Des-
mopressin (78% yield).
EXAMPLE 10
Preparation of Insulin loaded microspheres
The same procedure was performed as in example 6,
except that 15 mg Insulin (Sigma 1-5500) were emulsified
directly in the polymer solution by vortex mixing for one
minute. The particle size of the insulin particles was
about 5-10 pm.
The resulting microparticles were spherical with a
particle diameter of 10-50 pm and contained 9.3% of Insu-
lin (88% yield)
EXAMPLE 11
Preparation of DNA loaded microspheres
The same procedure was performed as in example 6,
except that 100 ul of Herring Sperm DNA (Promega)(10
mg/ml) were used for encapsulation.
The resulting microparticles were spherical with a
particle diameter of 10-50 pm and contained 0.07% of DNA
(10% yield).
EXAMPLE 12
Preparation of Bovine Serum Albumin in 50% PEG 10k
The same procedure was performed as in example 6,
except that 50% of PEG 10k was used as the external
phase.
The resulting microparticles were spherical and con-
tained 1.77% of BSA. This should be compared to 6.3% in
CA 02306824 2000-04-17
WO 99/20253 PCT/SE98/01717
example 1.
EXAMPLE 13
Preparation of Bovine Serum Albumin in 30% PEG 35k
5 The same procedure was performed as in example 1 ex-
cept that 30% of PEG 35k was used as the external phase.
The resulting microparticles were spherical and con-
tained 5.42% of BSA. This should be compared to a core
load of 6.3% in example 1.
